Enanta Pharmaceuticals financials
$12.64+0.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.4M | $17.2M | $18.6M | $15.1M | $18.3M | $14.9M | $17.0M | $14.6M | $18.0M | $17.1M | $18.0M | $18.9M |
| Gross profit | $14.4M | $17.2M | $18.6M | $15.1M | $18.3M | $14.9M | $17.0M | $14.6M | $18.0M | $17.1M | $18.0M | $18.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$17.2M | -$11.9M | -$11.3M | -$18.4M | -$18.9M | -$24.5M | -$23.5M | -$29.9M | -$24.2M | -$32.8M | -$34.9M | -$31.0M |
| Net income | -$19.5M | -$13.1M | -$11.9M | -$18.7M | -$18.3M | -$22.6M | -$22.3M | -$28.8M | -$22.7M | -$31.2M | -$33.4M | -$28.1M |
| Net margin | −135.8% | −76.3% | −64.1% | −123.6% | −99.7% | −151.7% | −131.4% | −197.3% | −126.1% | −182.7% | −185.6% | −148.5% |
| Diluted EPS | $-0.67 | $-0.45 | $-0.42 | $-0.87 | $-0.85 | $-1.06 | $-1.05 | $-1.36 | $-1.07 | $-1.47 | $-1.58 | $-1.36 |
| EBITDA | -$16.1M | -$10.6M | -$10.0M | -$17.1M | -$17.7M | -$23.3M | -$22.7M | -$29.4M | -$23.6M | -$32.1M | -$34.2M | -$31.0M |
| Operating cash flow | -$10.0M | -$7.2M | -$11.7M | -$6.5M | $17.5M | -$13.5M | -$16.8M | -$10.4M | -$14.8M | -$28.6M | -$25.0M | -$21.6M |
| Free cash flow | -$10.0M | -$7.2M | -$11.8M | -$7.9M | $17.4M | -$16.0M | -$25.5M | -$19.4M | -$21.3M | -$30.3M | -$25.8M | -$23.0M |
| Diluted shares | 29.1M | 29.0M | 28.7M | 21.4M | 21.4M | 21.4M | 21.2M | 21.2M | 21.2M | 21.2M | 21.1M | 20.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.4M | $34.9M | $37.4M | $32.3M | $44.8M | $60.2M |
| Short-term investments | $156.1M | $128.8M | $148.4M | $156.6M | $159.3M | $133.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $296.9M | $314.7M | $329.5M | $280.7M | $301.0M | $323.0M |
| Total liabilities | $195.8M | $198.1M | $202.9M | $216.0M | $221.8M | $229.5M |
| Shareholders' equity | $101.1M | $116.6M | $126.6M | $64.7M | $79.3M | $93.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology